Articles

Poll

Podcasts

Slideshows

Videos

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Mease outlined positive efficacy and safety findings from multiple long-term follow-up trials of the biologic in people with PsA and AxSpA.

Bimekizumab Demonstrates Long-Term Benefit for Arthritis Post-Approval, with Philip Mease, MD

Presented at SDPA, the FOREMOST Trial showed apremilast reduces joint burden and improves function in early oligo PsA through week 48.


Apremilast Shows Long-Term Benefit in Early Oligoarticular Psoriatic Arthritis

Depressive symptoms in the first 2 years after diagnosis were linked to lower odds of achieving remission in both RA and PsA.

Depression Reduces Remission Likelihood in Rheumatoid, Psoriatic Arthritis

New Phase 3 trial results reveal deucravacitinib's effectiveness in treating active psoriatic arthritis, offering hope for improved patient outcomes.

Phase 3 Deucravacitinib Trial Meets ACR20 End Point in PsA

New research highlights deucravacitinib's effectiveness in alleviating both skin and joint symptoms in people with both psoriasis and psoriatic arthritis.

Deuvacratinib Found to Concurrently Improve Psoriasis and Arthritis

Patients with concurrent type 2 diabetes mellitus and psoriatic arthritis who have a BMI below 30 kg/m2 exhibit higher all-cause mortality and lower 5-year survivability than those with higher BMI measurements.

Cardiovascular Risk Higher in Patients with Low BMI, Study Suggests

The rheumatology month in review emphasizes new research in gout burden, fibromyalgia management, and innovative lupus treatments.

Rheumatology Month in Review: May 2025

A recent study reveals significant variations in biologic use among pregnant patients with autoimmune diseases, highlighting the need for tailored risk-benefit assessments.

Research Finds Variable Biologic Use for Autoimmune Diseases During and After Pregnancy 

Secukinumab Demonstrates Long-Term Safety for Psoriasis and PsA

Intensive DMARD treatments significantly reduce pain in rheumatoid and psoriatic arthritis, shifting focus from opioids to effective pain management strategies.

DMARD-Based Strategies Provide Clinically Relevant Pain Relief in RA and PsA

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.